(Q38105879)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665679%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665679%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

0 references

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665679%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

E Sokolowski

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665679%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

C B Turina

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665679%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

D M Langenau

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665679%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

C Keller

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665679%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

language of work or name

English

0 references

publication date

13 May 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665679%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665679%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665679%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

1877-1889

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665679%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665679%20AND%20SRC:MED&resulttype=core&format=json

describes a project that uses

1 March 2020

0 references

0 references

0 references

0 references

0 references

https://scigraph.springernature.com/pub.10.1038/onc.2013.129

0 references

cites work

Common musculoskeletal tumors of childhood and adolescence

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Incidence and time trends of soft tissue sarcomas in German children 1985-2004 - a report from the population-based German Childhood Cancer Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Metastatic rhabdomyosarcoma: a retrospective review of patients treated at the hospital for sick children between 1989 and 1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Effects of RAS on the genesis of embryonal rhabdomyosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Rare cancer trial design: lessons from FDA approvals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Intercohort gene expression co-analysis reveals chemokine receptors as prognostic indicators in Ewing's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Proteasome inhibitors in multiple myeloma: 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

FDA approves pralatrexate for treatment of rare lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Educational paper. The development of new therapies for pediatric oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Clofarabine: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Challenges and opportunities in childhood cancer drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

The FDA Safety and Innovation Act.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

User fees and beyond--the FDA Safety and Innovation Act of 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Targeting developmental pathways in children with cancer: what price success?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Mutation and expression analyses of the MET and CDKN2A genes in rhabdomyosarcoma with emphasis on MET overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Rhabdomyosarcoma of the head and neck: a clinicopathological and immunohistochemical analysis of 29 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

p53 family members in myogenic differentiation and rhabdomyosarcoma development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Disabling c-Myc in childhood medulloblastoma and atypical teratoid/rhabdoid tumor cells by the potent G-quadruplex interactive agent S2T1-6OTD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

ALK protein expression in rhabdomyosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Anaplastic lymphoma kinase status in rhabdomyosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

C-kit expression in pediatric solid tumors: a comparative immunohistochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Clinical significance of CXC chemokine receptor-4 and c-Met in childhood rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Systemic analysis of gene expression profiles identifies ErbB3 as a potential drug target in pediatric alveolar rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

FGFR1 over-expression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5' CpG island and abnormal expression of the AKT1, NOG, and BMP4 genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

RAS signaling dysregulation in human embryonal Rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Beta-catenin mutation does not seem to have an effect on the tumorigenesis of pediatric rhabdomyosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Deregulation of the hedgehog signalling pathway: a possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report from the Children's Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Notch pathway inhibition significantly reduces rhabdomyosarcoma invasiveness and mobility in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Caveolins in rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

IL-4R drives dedifferentiation, mitogenesis, and metastasis in rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Immunohistochemical detection of EGFR, fibrillin-2, P-cadherin and AP2beta as biomarkers for rhabdomyosarcoma diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Different telomere maintenance mechanisms in alveolar and embryonal rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Dystrophin and dysferlin double mutant mice: a novel model for rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Induction of a regenerative microenvironment in skeletal muscle is sufficient to induce embryonal rhabdomyosarcoma in p53-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Histone methyltransferase KMT1A restrains entry of alveolar rhabdomyosarcoma cells into a myogenic differentiated state

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Significance of persistent mature rhabdomyoblasts in bladder/prostate rhabdomyosarcoma: Results from IRS IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Epigenetic and epigenomic mechanisms shape sarcoma and other mesenchymal tumor pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Defining the gene expression signature of rhabdomyosarcoma by meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Targeting the fetal acetylcholine receptor in rhabdomyosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Association of neonatal myasthenia gravis with antibodies against the fetal acetylcholine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Immuno-analysis and FACS sorting of adult muscle fiber-associated stem/precursor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Targeting the fanconi anemia pathway to identify tailored anticancer therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Differential PAX3 functions in normal skin melanocytes and melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Molecular staging of pathologically negative sentinel lymph nodes from melanoma patients using multimarker, quantitative real-time rt-PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Identification of target genes regulated by PAX3 and PAX3-FKHR in embryogenesis and alveolar rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Molecular characterization of the pediatric preclinical testing panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Developmental origins of fusion-negative rhabdomyosarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Immune competency of a hairless mouse strain for improved preclinical studies in genetically engineered mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

The pediatric preclinical testing program: description of models and early testing results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Massive genomic rearrangement acquired in a single catastrophic event during cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

T (brachyury) gene duplication confers major susceptibility to familial chordoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Overcoming autopsy barriers in pediatric cancer research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

The clinical, research, and social value of autopsy after any cancer death: a perspective from the Children's Oncology Group Soft Tissue Sarcoma Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Identification of FoxM1/Bub1b signaling pathway as a required component for growth and survival of rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Caveolin 1 is a marker of poor differentiation in Rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Selective usage of D-Type cyclins by Ewing's tumors and rhabdomyosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Ceramide-induced G2 arrest in rhabdomyosarcoma (RMS) cells requires p21Cip1/Waf1 induction and is prevented by MDM2 overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Amplification of MDM2 inhibits MyoD-mediated myogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Molecular cytogenetic characterization of rhabdomyosarcoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Impaired nonhomologous end-joining provokes soft tissue sarcomas harboring chromosomal translocations, amplifications, and deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Production of stem cell factor and expression of c-kit in human rhabdomyosarcoma cells: lack of autocrine growth modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Inhibition of rhabdomyosarcoma's metastatic behavior through downregulation of MET receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Role of I-TAC-binding receptors CXCR3 and CXCR7 in proliferation, activation of intracellular signaling pathways and migration of various tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Redundancy of autocrine loops in human rhabdomyosarcoma cells: induction of differentiation by suramin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Sp1-mediated transcriptional control of fibroblast growth factor receptor 4 in sarcomas of skeletal muscle lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Reduction of human embryonal rhabdomyosarcoma tumor growth by inhibition of the hedgehog signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Betulinic acid induces apoptosis and inhibits hedgehog signalling in rhabdomyosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Patched2 modulates tumorigenesis in patched1 heterozygous mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Loss of suppressor-of-fused function promotes tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Expression of H-RASV12 in a zebrafish model of Costello syndrome causes cellular senescence in adult proliferating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x(L).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

18F-FDG microPET imaging detects early transient response to an IGF1R inhibitor in genetically engineered rhabdomyosarcoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Leukemia inhibitory factor: a newly identified metastatic factor in rhabdomyosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

MDM2 displays differential activities dependent upon the activation status of NFkappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Sarcomas induced in discrete subsets of prospectively isolated skeletal muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Concomitant amplification and expression of PAX7-FKHR and MYCN in a human rhabdomyosarcoma cell line carrying a cryptic t(1;13)(p36;q14).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Characterization of an embryonal rhabdomyosarcoma cell line showing amplification and over-expression of the N-myc oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumour cell growth in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Co-injection strategies to modify radiation sensitivity and tumor initiation in transgenic Zebrafish

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

PAX3 and PAX3-FKHR promote rhabdomyosarcoma cell survival through downregulation of PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

PAX3-FKHR transformation increases 26 S proteasome-dependent degradation of p27Kip1, a potential role for elevated Skp2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Novel small molecule, XZH-5, inhibits constitutive and interleukin-6-induced STAT3 phosphorylation in human rhabdomyosarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Novel mechanism of action on Hedgehog signaling by a suppressor of fused carboxy terminal variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

TGF-beta1 signal pathway may contribute to rhabdomyosarcoma development by inhibiting differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Systematic analysis of the TGF-beta/Smad signalling pathway in the rhabdomyosarcoma cell line RD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Rhabdomyosarcoma development in mice lacking Trp53 and Fos

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Rhabdomyosarcoma in children: a SEER population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Seattle Genetics rare cancer drug sails through accelerated approval

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

The Children's Oncology Group's 2013 five year blueprint for research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Mutation analysis of p53 gene in childhood malignant solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, andCDKN2C) in childhood rhabdomyosarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

N-myc gene is amplified in alveolar rhabdomyosarcomas (RMS) but not in embryonal RMS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Caveolin-3 is a sensitive and specific marker for rhabdomyosarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

The long road to immunotherapy for childhood rhabdomyosarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Drug approvals 2011: focus on companion diagnostics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Results of a prospective minimal disseminated disease study in human rhabdomyosarcoma using three different molecular markers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Expression of HER/erbB family of receptor tyrosine kinases and induction of differentiation by glial growth factor 2 in human rhabdomyosarcoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129

Uncommitted precursor cells might contribute to increased incidence of embryonal rhabdomyosarcoma in heterozygous Patched1-mutant mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.129